Learn more about investing in Laguna Bio

Our team will get back to you soon to follow up on your inquiry.
Lead Rounds?
Laguna Bio
The newest cancer killers on the block
Founded
2022
Employees*
2
Funding to Date*
$275,000
CEO Jonathan Kotula, PhD
"γδ T cells can uniquely generate robust and durable cytotoxicity against cancer and nothing produces more (gamma delta) T cells than Laguna Listeria."
2 out of 3 patients with solid tumors don’t experience a robust anti-tumor response, even with cutting-edge cancer therapies

Laguna Bio is perfecting an entirely new approach to selectively activate and expand a specific type of T cell, the gamma-delta T (γδ T) cells, to take full advantage of the immune system’s ability to fight solid tumors. The γδ T cells are an obscure but homogeneous population of immune cells that you can count on to kill cancer cells. CAR-γδ T cells have shown success in clinical studies of B-cell lymphoma; Allogeneic γδ T cells have already shown promise in liver and lung cancers.

Building on a collaborator’s positive human data and from live-attenuated Listeria, Laguna is designing a proprietary Listeria to be the safest and most robust yet highly selective activator of these T cells. Increasing response rate of a bispecific antibody drug using Laguna’s listeria would be a major advance for those with solid tumors and represents a multi-billion dollar opportunity.